Longboard Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Updates
Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today provided a corporate update and reported first quarter 2024 financial results.
- Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today provided a corporate update and reported first quarter 2024 financial results.
- In January 2024, Longboard raised $241.5 million in a follow-on public offering.
- Longboard issued and sold 11,500,000 shares of common stock at a public offering price of $21.00 per share.
- In March 2024, Longboard completed a Private Placement with an investment fund affiliated with Farallon Capital Management, L.L.C.